AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Eupraxia: Cantor Fitzgerald initiates at 'Overweight' Rating, The Target Price is $11
ByAinvest
Thursday, Jul 24, 2025 8:00 am ET1min read
Cantor Fitzgerald initiates coverage on 'Overweight' rating on Eupraxia(EPRX).
The target price is $11.
[Recent Rating]
| Date | Agency | Change | Rating | Rating （previously） | Target Price | Target Price（previously） |
|---|---|---|---|---|---|---|
| 2025-07-24 | Cantor Fitzgerald | Initiates Coverage On | Overweight | -- | $11 | $-- |
| 2025-06-26 | HC Wainwright & Co. | Initiates Coverage On | Buy | -- | $12 | $-- |
[Recent Earning Results] Eupraxia posted the Q1 of its 2025 financial results on 5/6/2025, reporting net income of USD -6.77 million in the first quarter, expanding 9.91% from USD -6.16 million year over year.
[Company Profile] Eupraxia Pharmaceuticals Inc. was incorporation in British Columbia on May 2011. Eupraxia is a clinical stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals to create novel products that are "first-time" uses for the molecule or drug class, or "best-in-class" products for indications where efficacy has already been established. Leveraging their proprietary and innovative DiffusphereTM delivery technology, Eupraxia's goal is to provide the right dose of drug, in the right place, for the right amount of time in indications with a high unmet medical need. Each of Eupraxia's product candidates are designed to achieve improved patient benefit by providing more prolonged activity than currently available treatments, combined with an improved pharmacokinetics ("PK") and related safety profile and combined with precisely targeted local delivery.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet